ClinicalTrials.gg
TerminatedNCT05372445MicrobiArUpdated Mar 16, 2026

Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention

An interventional study of Non-intensive intervention and Intensive intervention in Diabetes Mellitus, Type 2, Obesity and PreDiabetes, sponsored by National Council of Scientific and Technical Research, Argentina. Terminated at 1 site in Argentina. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by National Council of Scientific and Technical Research, Argentina · Not applicable, Interventional, and Treatment

Why this study was terminated
Recruitment was discontinued due to Argentina severe socio-economic crisis, which significantly impacted hospital operations and research funding. The loss of financial support prevented further enrollment and coverage of clinical and lab assessments
Phase
Not applicable
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Study summary

The incidence of type 2 diabetes worldwide is growing rapidly, being one of the fastest growing global health emergencies of the 21st century according to the International Diabetes Federation. In MicrobiAr the investigators seek to achieve type 2 diabetes remission through a plant-based diet and lifestyle intervention identifying and characterizing key changes on the gut microbiome during clinical transitions. Specifically, the investigators aim to characterize and follow-up metabolic pathways from gut microbiome and how they evolve as long as health indicators do over the 2 years of this study.

Read the detailed description

The present study has 2 stages, one cross-sectional and the other longitudinal. In the cross-sectional stage, a characterization of a single sampling of 480 people divided into 4 cohorts of 120 people each will be carried out: reference controls, subjects with obesity, with prediabetes and with type 2 diabetes. A clinical history will be made, as long as a 7-day food record and clinical laboratory tests. Anthropometric assessment will be carried out by recording weight, height, waist and hip circumference, determination of waist/hip ratios, as well as taking 4 skinfolds, bicipital, triceps, subscapular and suprailiac, arm and calf measurements and force through a dynamometer. The 480 people will also undergo gut microbiota and microbiome tests from stool samples.

During the longitudinal stage, subjects of each cohort (120 with obesity, 120 with prediabetes and 120 with type 2 diabetes) will be randomly divided into two intervention groups (with 60 subjects each). One group will follow a non-intensive intervention (personalized face-to-face follow-up every 2 months). The other group will follow an intensive intervention (personalized face-to-face follow-up every 3 weeks and a weekly remote group meeting). In both cases, a food plan will be followed based on the recommendations of the nutrition service of the Hospital de Clínicas, Argentina, in accordance with recommendations from the American Diabetes Association (ADA) 2019 guidelines with an emphasis on plant-based diet and whole foods.

Follow-up and nutritional guidance

Groups of 15 subjects from each intervention arm will be led by 3 healthcare professionals. In every case, the group's functions will be:

  1. Obtain a unique 7 day food-recall from all subjects, and upload the data to "MAR24" platform (for the transversal stage).
  2. Obtain a 2 day food-recall (including one day from the weekend) from all subjects every two months, and upload the data to "MAR24" platform (for the longitudinal stage).
  3. Complete a shared spreadsheet with clinical, biochemical and anthropometric parameters of every subject's visits to the hospital.
  4. Collaborate in Whatsapp unidirectional groups. In the non-intensive arm, the messages will only be to remember patients about their visits to the hospital, while in the intensive arm it will also be about other activities, such as workshops.
  5. Detect subjects who miss their appointments, to establish personalized contact and apply motivational strategies in order to reduce dropout risk.

To accomplish the mentioned tasks, the group leaders will have support from several students from nutrition careers and healthcare professionals.

Influence of physical activity and exercise

A structured physical exercise protocol will be delivered to all subjects. This protocol includes a warm-up, 3 series of 1 minute of eight different strength exercises, with 2 a minute rest. The objective is to accomplish three sessions per week, which can be done in person and supervised by specialists in the Hospital, or online via video call. Subjects will have to record the amount of achieved repetitions in each series of every exercise already done by each session.

The training volume will be adapted according to the subject's capabilities and progress, with the objective of increasing the number of series and reducing resting time between exercises.

Specific follow-up and support proposals for the intensive intervention

In addition to the already mentioned tasks in the follow-up and nutritional guidance's section, for the intensive intervention subjects, group's functions will also be:

  1. Collaborate in the assembly and execution of virtual food education workshops;
  2. Coordinate weekly meetings with the 15 assigned subjects, where adherence should be encouraged during the first 3 months. Then, meetings will be spaced out at a minimum of 15 days to 30 days;
  3. Contribute to the planning of various activities that seek to maximize adherence to the clinical trial of the entire intensive intervention group;
  4. Coordinate face-to-face visits for nutritional support every 3 weeks for each subject;
  5. Monitoring adherence through 48-hour records (1 day a week and 1 day a weekend) using the MAR24 platform. Data will be collected by phone calls or video calls to each subject with a frequency of 1 call per month.
02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
  • PreDiabetes

Keywords

  • microbiota
  • microbiome
  • plant-based diet
  • type 2 diabetes remission
  • metabolic syndrome
  • caloric restriction
  • metabolic pathways
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's enrollment of 468 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

National Council of Scientific and Technical Research, Argentina is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for control or reference group:

  • Subjects without type 2 diabetes, obesity, prediabetes (glucose intolerance), or metabolic syndrome
  • less than 42mmol/mol (\<5.7%)
  • between 18.5 and 24.9

Inclusion Criteria for people with obesity:

  • BMI greater than 30

Inclusion Criteria for people with prediabetes:

  • Fasting glucose between 110 and 125 mg/dl
  • HbA1c between 42 and 47 mmol/mol (5.7% to 6.4%)
  • BMI greater than 30

Inclusion Criteria for people with type 2 diabetes:

  • Fasting glucose > 126 mg/dl
  • HbA1c > 48mmol/mol (6.5% or higher)
  • BMI greater than 30
  • Treatment with metformin at therapeutic dose (1500-2000 mg/day) or maximum tolerated dose.

Exclusion Criteria:

  • Subjects with obesity, pre-diabetes medicated with metformin or another drug for diabetes or obesity
  • Subjects with type 2 diabetes medicated with another drug that is not metformin
  • Subjects with type 2 diabetes diagnosed over 6 years
  • Subjects with type 2 diabetes requiring insulin
  • Chronic kidney disease grade greater than 3 (measured by EPI)
  • Subjects with type 1 diabetes
  • Intestinal diseases, Crohn's, ulcerative colitis, celiac disease
  • Use of antibiotics in the last 3 months
  • Pregnancy, lactation
  • Psychiatric disorders
  • Eating disorder
  • Gastric bypass surgery
  • Transplanted people
  • Oncological pathology diagnosed less than 5 years
  • Subjects who do not wish to sign the
  • Subjects who do not agree to participate in the study over the 2 years follow-up
  • Subjects who do not have electronic devices and the internet to hold virtual meetings
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
468 participants (actual)

Study arms

  • No intervention
    Reference Group

    People between 30-60 years old, without obesity, prediabetes or type 2 diabetes. The purpose of this group is to characterize gut microbiota and microbiome to set the reference values of the argentinian local population.

  • Active comparator
    Obesity Group A

    People between 30-60 years old, diagnosed with obesity assigned to the non-intensive intervention.

    Behavioral: Non-intensive intervention

  • Experimental
    Obesity Group B

    People between 30-60 years old, diagnosed with obesity assigned to the intensive intervention.

    Behavioral: Intensive intervention

  • Active comparator
    Prediabetes Group A

    People between 30-60 years old, diagnosed with prediabetes assigned to the non-intensive intervention.

    Behavioral: Non-intensive intervention

  • Experimental
    Prediabetes Group B

    People between 30-60 years old, diagnosed with prediabetes assigned to the intensive intervention.

    Behavioral: Intensive intervention

  • Active comparator
    Type 2 Diabetes Group A

    People between 30-60 years old, diagnosed with type 2 diabetes assigned to the non-intensive intervention.

    Behavioral: Non-intensive intervention

  • Experimental
    Type 2 Diabetes Group B

    People between 30-60 years old, diagnosed with type 2 diabetes assigned to the intensive intervention.

    Behavioral: Intensive intervention

Interventions

  • BehavioralNon-intensive intervention

    After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population. The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls.

    Also known as: Group A

  • BehavioralIntensive intervention

    People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks. The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention.

    Also known as: Group B

06

What researchers measure

Primary outcomes

  1. Clinical improvements in people with type 2 diabetes, prediabetes, or obesity

    These clinical improvements will be defined as: 1. In the group of subjects with type 2 diabetes, remission to non-diabetic stage. Considering remission as measuring HbA1c values lower than 6,5% at least 6 months after beginning the lifestyle intervention and 3 months after cessation of any pharmacotherapy, according to the "Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes", Diabetes Care 2021;44(10):2438-2444. 2. In the group of subjects with prediabetes, remission to normal glycemia / HbA1c values. Considering normal glycemia lower than 100 mg/gl and HbA1c lower than 5.7%. 3. In the group of overweight-obese subjects, a 10% decrease in weight compared to baseline weight, maintained during the second year of follow-up. Any of the three possible situations will be considered as a clinical improvement event.

    Time frame: at 2 years, checked every 6 months

  2. Gut microbiota metabolic pathways changes

    Increase in the number of gut microbiota metabolic pathways possibly expressed in subjects of intensive intervention compared to their baseline states and also compared to subjects of the non-intensive intervention. This metric refers to possibly expressed metabolic pathways predicted from shotgun metagenomics analysis related to regulation of inflammatory processes, carcinogenesis, intestinal barrier function, oxidative stress, production of SCFAs, regulation of immune response and inflammation, production of derivative aromatic amino acids, regulation of bile acids (synthesis of derivative metabolites of cholesterol), regulation of the level of phospholipid synthesis (anaerobic metabolism of choline).

    Time frame: at 2 years, checked every 6 months

Secondary outcomes

  1. Metabolic syndrome regression

    Participants with diagnosis of metabolic syndrome at baseline who no longer meet metabolic syndrome criteria, according to those established by the Joint Interim Statement in 2009 (Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640 -1645.)

    Time frame: at 2 years, checked every 6 months

  2. Insulin resistance

    Measured by HOMA-IR, HOMA-B or triglyceride: HDL-C ratio.

    Time frame: at 2 years

  3. Gut microbiota diversity changes

    Increase of diversity in gut microbiota observed in subjects of the intensive intervention compared to subjects of the non-intensive intervention and also compared to their baseline states.

    Time frame: at 2 years, checked every 6 months

07

Study locations

1 site
  • Hospital de Clínicas "José de San Martín"
    Capital Federal, Buenos Aires C1120AAR, Argentina
08

References and documents

Publications

  • Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5. PubMed 19805654 ↗
  • Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021 Aug 30;44(10):2438-44. doi: 10.2337/dci21-0034. Online ahead of print. PubMed 34462270 ↗

Individual participant data

Plan to share: Yes — all required data in order to reproduce the publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: starting immediately after publication in a peer reviewed journal

Access criteria: all required data in order to reproduce the publication will be full available in our website www.microbiar.com through a specific section that will be implemented for this aim.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jul 2025, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2022
First posted
May 12, 2022
StartActual
May 30, 2022
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05372445
Lead sponsor
National Council of Scientific and Technical Research, Argentina
Collaborators
Facultad de Ingeniería - Universidad Austral, Instituto de Inmunología, Genética y Metabolismo (INIGEM, CONICET-UBA), Illumina, Inc., Zymo Research, Instituto de Investigación y Desarrollo en Bioingeniería y Bioinformática (IBB, CONICET-UNER)
Responsible party
Juan Pablo Bustamante (Bioinformatician, PhD in Biological Chemistry, National Council of Scientific and Technical Research, Argentina) — Principal investigator
First posted
May 12, 2022
Start date
May 30, 2022
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Last update
Mar 16, 2026

Study contacts

Juan Bustamante, PhD
principal investigator · CONICET Researcher
Gustavo Frechtel, PhD
principal investigator · CONICET Researcher

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion